OpenArray PCR Platform Detects Pathogens in Plasma, Blood

This article originally appeared here.
Share this content:
OpenArray PCR Platform Detects Pathogens in Plasma, Blood
OpenArray PCR Platform Detects Pathogens in Plasma, Blood

WEDNESDAY, June 14, 2017 (HealthDay News) -- The high-throughput OpenArray polymerase chain reaction (PCR) platform can detect and discriminate agents in plasma and blood samples, according to a study published online June 14 in the Journal of Molecular Diagnostics.

Elena Grigorenko, Ph.D., from Diatherix Laboratories LLC, in Huntsville, Ala., and colleagues developed a highly multiplexed blood-borne pathogen panel (BBPP) using dual-label probe chemistry. The panel was used for simultaneous detection and discrimination of 17 viral pathogens in human plasma samples and 13 bacterial and protozoan pathogens in human blood samples. Purified nucleic acids from each pathogen and with pathogen-spiked human blood and plasma samples were used to test the specificity and analytical sensitivity of the custom BBPP OpenArray plate.

The researchers found that there were no false positives among the plasma or whole blood specimens. Samples that were not detected were at the lower limit of the detectable range or were indeterminate and qualified for retesting. Using clinical samples from a blood donor testing organization, 95 percent of virus-positive samples were identified correctly.

"These results show that a high-throughput OpenArray PCR platform can be expanded and adapted for higher discrimination and newly emerging agents, enabling consideration for development as a next-generation device for testing blood products," the authors write.

Several authors are employees of biopharmaceutical companies, including Thermo Fisher Scientific, the manufacturer of the OpenArray platform.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »